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Sirolimus-Paclitaxel Comparison
essel Size and Outcome After
oronary Drug-Eluting Stent Placement
esults From a Large Cohort of Patients
reated With Sirolimus- or Paclitaxel-Eluting Stents
hpend Elezi, MD,* Alban Dibra, MD,* Julinda Mehilli, MD,* Jürgen Pache, MD,* Rainer Wessely, MD,*
lbert Schömig, MD,† Adnan Kastrati, MD*
unich, Germany
OBJECTIVES This study sought to investigate the influence of vessel size on the outcomes of patients after
drug-eluting stent (DES) implantation.
BACKGROUND There are no dedicated studies on the influence of vessel size on the outcomes of patients
treated with different DES.
METHODS The study population was composed of 2,058 consecutive patients who received sirolimus-
eluting stents (SES) or paclitaxel-eluting stents (PES). Patients were grouped into tertiles
according to vessel size (2.41 mm in the lower tertile, 2.41 to 2.84 mm in the middle tertile,
and2.84 mm in the upper tertile). The primary end point was target lesion revascularization
(TLR). Secondary end points were binary angiographic restenosis and the composite of death
or myocardial infarction.
RESULTS Vessel size did not influence the composite end point of death and myocardial infarction. The
TLR rates were higher among patients in the lower tertile (12.1%) as compared with the
middle (8.4%) and upper (8.0%) tertiles (p  0.02). In a multivariate analysis, vessel size
emerged an independent predictor of TLR (p  0.009). The model showed also a significant
interaction between DES type and vessel size regarding TLR (p  0.008). There was a
significant difference in TLR rates among patients treated with SESs (8.6%) and PESs
(16.4%) in the lower tertile (p  0.002), but not in the middle and upper tertiles.
CONCLUSIONS The influence of vessel size on restenosis is related to the specific DES used, with SESs
providing better outcomes than PESs in small but not in large coronary vessels. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.068Cardiol 2006;48:1304–9) © 2006 by the American College of Cardiology Foundation
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(essel size is an important determinant of outcomes in
atients who undergo percutaneous coronary interventions
1–4). Small reference diameter has been associated with an
ncreased risk of restenosis. In patients treated with bare-
etal stents (BMS), the impact of vessel size is quite
bvious because of the limited ability of small size vessels to
ccommodate for the neointimal proliferation that develops
fter stent implantation (5,6). This explains the failure of
everal studies to establish the superiority of BMS over plain
alloon angioplasty in patients treated for lesions located in
mall coronary vessels (5,7–11).
See page 1310
Several drug-eluting stent (DES) platforms have been
ery successful in reducing restenosis risk compared with
From the *Deutsches Herzzentrum, Technische Universität, and †First Mediz-
nische Klinik rechts der Isar, Technische Universität, Munich, Germany. Dr.
astrati has received lecture fees from Bristol-Myers Squibb, Cordis, Glaxo, Lilly,
edtronic, and Sanofi-Aventis.o
Manuscript received February 27, 2006; revised manuscript received May 3, 2006,
ccepted May 16, 2006.MSs after implantation in patients with coronary artery
isease (12–18). The advantages of DES over BMS have
een shown in different subsets of patients and lesions,
ncluding that of small coronary vessels (7,19–22). The
ntirestenotic efficacy of DES is achieved through inhibi-
ion of neointimal proliferation, which is shown angio-
raphically by the reduced degree of late lumen loss.
ecause of the much lower lumen loss rates achieved with
ES as compared with BMS, some have suggested that the
mpact of vessel size may be attenuated or even cancelled after
ES implantation (23). Recent analyses have shown that
essel size plays a major role even in the DES era (20,24).
owever, previous studies have included only small to mod-
rate numbers of selected patients, who have been treated with
single type of DES. It is also not known whether the
nfluence of vessel size is related to the type of DES used.
The objective of this study was to investigate the impact
f vessel size on the clinical and angiographic outcomes after
oronary implantation of the 2 U.S. Food and Drug
dministration–approved DES, the sirolimus-eluting stents
SES) and paclitaxel-eluting stents (PES), in a large series
f consecutive patients.
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atient population. The study population was composed
f 2,058 consecutive patients who received polymer-based
ES (Cypher, Cordis Corporation, Miami Lakes, Florida)
r PES (Taxus, Boston Scientific Corporation, Natick,
assachusetts) in Deutsches Herzzentrum and First
edizinische Klinik rechts der Isar, Munich, Germany,
rom August 2002 through March 2005. Excluded from
his study were patients with cardiogenic shock, acute
T-segment elevation myocardial infarction, or target lesion
ocated in unprotected left main coronary artery or venous
ypass graft. A loading dose of 600 mg clopidogrel was
dministered to all patients at least 2 h before coronary
ngiography. Periprocedural antithrombotic therapy con-
isted of intravenous aspirin and heparin. After the inter-
ention, the protocol mandated antiplatelet therapy consist-
ng of aspirin 100 mg twice per day indefinitely as well as
lopidogrel 75 mg twice per day until discharge and 75 mg
er day for at least 6 months.
ollow-up protocol. After the stenting procedure, all pa-
ients remained in the hospital for at least 48 h. Electrocar-
iograms were recorded, and blood was collected for deter-
ination of creatine kinase and its MB isoenzyme before
tenting, every 8 h for the first 24 h after the procedure, and
aily afterward. A telephone interview after 30 days was
one to assess each patient’s clinical status. All patients were
sked to return for coronary angiography between 6 and 8
onths after the procedure or earlier if anginal symptoms had
eveloped. Phone interviews were repeated at 9 months after
he intervention. All patients with symptoms considered to be
ossibly cardiac in origin underwent a complete clinical,
lectrocardiographic, and laboratory evaluation at the out-
atient clinic. When necessary, an angiographic study was
erformed. Relevant data were prospectively collected and
ntered into a computer database by specialized personnel.
uantitative coronary angiography evaluation. Baseline,
ostprocedural, and follow-up coronary angiograms were
igitally recorded and assessed off-line in the Quantitative
ngiographic Core Laboratory (Deutsches Herzzentrum,
unich, Germany) with the use of an automated edge
etection system (CMS version 6.0.10.0, Medis Medical
maging Systems, Nuenen, the Netherlands) by experienced
ersonnel. The complexity of the lesions was defined according
o the modified American College of Cardiology/American
eart Association grading system (25). All measurements were
erformed on cineangiograms recorded after intracoronary
Abbreviations and Acronyms
BMS  bare-metal stent
DES  drug-eluting stent
PES  paclitaxel-eluting stent
SES  sirolimus-eluting stent
TLR  target lesion revascularizationitroglycerin administration. The same single, worst-view srojection was used at all time points. The contrast-filled
ontapered catheter tip was used for calibration. The param-
ters that were measured included the reference diameter of the
essel, the minimal lumen diameter, percent diameter stenosis
difference between the reference diameter and minimal lumen
iameter divided by the reference diameter and multiplied by
00), and late lumen loss (difference between minimal lumen
iameter at the end of the procedure and minimal lumen
iameter at follow-up). Quantitative analysis was performed in
he in-stent area (in-stent analysis) and in the in-segment area
ncluding the stented segment as well as both 5-mm margins
roximal and distal to the stent (in-segment analysis).
tudy end points and definitions. The primary end point
f the study was the need for target lesion revascularization
TLR), which was defined as any revascularization proce-
ure, percutaneous or surgical, involving the target lesion
erformed in the presence of symptoms or objective signs of
schemia during the 9-month follow-up interval. Secondary
nd points were in-segment binary angiographic restenosis,
efined as a diameter stenosis50% at control angiography,
nd the composite of death or myocardial infarction. The
iagnosis of myocardial infarction during the follow-up
equired the presence of new Q waves in the electrocardio-
ram and/or an elevation of creatine kinase or its MB
soenzyme to at least 3 times the upper limit of normal in at
east 2 blood samples.
tatistical analysis. Statistical analysis was performed us-
ng a per-patient approach. In patients with a multilesion
ntervention, only 1 lesion was selected randomly for anal-
sis. The random selection was performed before the
nalysis of the data by assigning a random number to each
esion and selecting for analysis the lesion with the smallest
andom number among patients with multilesion interven-
ion. The adequacy of this method was checked by evalu-
ting the reproducibility of the results after selecting the
esion with the greatest random number.
To study the clinical and angiographic outcome for
ifferent ranges of vessel size, we grouped the study popu-
ation in tertiles according to the reference diameter. The
utoff points of reference diameter that divided the popu-
ation into 3 equally sized groups were 2.41 and 2.84 mm:
he lower tertile included patients with vessel size 2.41
m; the middle tertile included patients with vessel size
.41 to 2.84, and the upper tertile included patients with
essel size 2.84 mm. Data are expressed as mean values 
D for continuous variables and as percentages for discrete
ariables. Differences between groups were assessed using
NOVA test for continuous and chi-square test for cate-
orical variables.
Multivariable logistic regression was used to investigate
otential independent risk factors for TLR. Baseline clinical
nd angiographic characteristics as well as procedural variables
ere entered into the model. Differences were considered to betatistically significant when the p values were 0.05.
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aseline characteristics. Basal clinical and angiographic
haracteristics are shown in Table 1. There were significant
ifferences across groups with respect to several variables
uch as gender, presence of diabetes mellitus, smoking
tatus, prior coronary bypass surgery, and so on. There were
o differences across study groups with respect to lesion
ength and complexity or to preprocedural diameter steno-
is. Procedural characteristics are shown in Table 2.
The proportion of patients with multilesion intervention
as 14.7% in the lower tertile, 12.4% in the middle tertile,
nd 11.2% in the upper tertile (p  0.14). When patients
ith multilesion intervention were analyzed separately by
ncluding all stented lesions and according to the stent type
eceived, there were no significant differences between the
ES and PES groups regarding important characteristics
uch as frequency of diabetes (p  0.85), vessel location of
he lesion (p  0.32), frequency of chronic occlusions (p 
able 1. Baseline Characteristics of the Patients and Lesions
Characteristic
Lower Te
<2.41 m
(n  67
ge, yrs 66.3  9
omen, no. (%) 172 (25.
iabetes mellitus, no. (%) 233 (34.
urrent smoker, no. (%) 68 (10.
rterial hypertension, no. (%) 406 (60.
ypercholesterolemia, no. (%) 500 (73.
nstable angina, no. (%) 173 (25.
rior myocardial infarction, no. (%) 274 (40.
rior aortocoronary bypass surgery, no. (%) 86 (12.
ultivessel disease, no. (%) 585 (86.
eft ventricular ejection fraction, % 55.5  1
arget vessel
Left anterior descending coronary artery, no. (%) 355 (52.
Left circumflex coronary artery, no. (%) 219 (32.
Right coronary artery, no. (%) 104 (15.
omplex (type B2/C) lesions, no. (%) 499 (73.
hronic occlusions, no. (%) 71 (10.
esion length, mm 13.3  7
inimal lumen diameter before procedure, mm 0.83  0
iameter stenosis before procedure, % 60.9  1
lus-minus values are mean  SD.
able 2. Procedural Characteristics
Characteristic
Lower Tertile
<2.41 mm
(n  678)
aximal balloon pressure, atm 13.9  2.8
alloon-to-vessel ratio 1.23  0.13
irolimus-eluting stents, no. (%) 373 (55.0)
ength of stented segment, mm 22.8  10.0
inimal lumen diameter after procedure
In-stent, mm 2.17  0.26
In-segment, mm 1.72  0.35
iameter stenosis after procedure
In-stent, % 6.7  7.2
In-segment, % 26.1  6.2lus-minus values are mean  SD..24) and complex lesions (p 0.80), vessel size (p 0.25),
nd length of stented segment (p  0.26). Lesion length
ended to be greater among patients with multilesion
ntervention who received SES as compared with those who
eceived PES (p  0.07).
During the first 30 days after the procedure, there were 7
1.0%) cases of stent thrombosis among patients grouped in
he lower tertile, 2 (0.3%) cases in the middle tertile, and 4
0.6%) cases in the upper tertile (p  0.22).
ngiographic outcome. Follow-up angiography at a me-
ian of 193 days (interquartile range 175 to 205 days) was
arried out in 1,666 patients (81%). Angiographic outcome
s presented in Table 3. In-stent late lumen loss was not
tatistically different between the 3 groups (p  0.29). The
ack of dependence of late lumen loss on vessel size was seen
rrespective of the type of DES used (Fig. 1). Diameter
tenosis at follow-up showed significant variation between
roups (p  0.001), having the highest values among
Middle Tertile
2.41 to 2.84 mm
(n  692)
Upper Tertile
>2.84 mm
(n  688) p Value
66.1  10.7 65.6  10.9 0.17
161 (23.3) 118 (17.2) 0.001
186 (26.9) 176 (25.6) 0.001
103 (14.9) 114 (16.6) 0.001
425 (61.5) 393 (57.1) 0.26
500 (72.3) 509 (74.0) 0.73
186 (26.9) 223 (32.4) 0.01
276 (40.0) 237 (34.5) 0.04
68 (9.8) 48 (7.0) 0.002
563 (81.4) 567 (82.4) 0.04
55.1  12.6 55.2  12.8 0.63
0.001
316 (45.7) 289 (42.0)
200 (28.9) 146 (21.2)
176 (25.4) 253 (36.8)
521 (75.3) 526 (76.5) 0.47
49 (7.1) 37 (5.4) 0.001
14.2  8.0 13.8  7.1 0.22
1.04  0.40 1.28  0.51 0.001
60.4  14.9 60.2  15.1 0.36
Middle Tertile
2.41 to 2.84 mm
(n  692)
Upper Tertile
>2.84 mm
(n  688) p Value
14.6  2.9 14.9  2.8 0.001
1.14  0.09 1.10  0.08 0.001
371 (53.6) 395 (57.4) 0.36
23.3  8.9 23.0  8.6 0.66
2.52  0.23 3.0  0.32 0.001
2.11  0.35 2.62  0.44 0.001
7.9  6.5 9.4  5.8 0.001
23.0  7.2 20.7  8.3 0.001rtile
m
8)
.5
4)
4)
0)
0)
7)
5)
4)
7)
3)
2.7
4)
3)
3)
6)
5)
.8
.33
5.4
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October 3, 2006:1304–9 Vessel Size and Outcome With Drug-Eluting Stentsatients grouped in the lower tertile. The incidence of the
ngiographic secondary end point of the study, in-segment
inary restenosis, was significantly different between groups
p  0.001).
linical outcome. After 9 months of clinical follow-up,
he number of patients who suffered death or myocardial
nfarction was not different across study groups: 40 (5.9%) in
he lower tertile, 35 (5.1%) in the middle tertile, and 36
5.2%) in the upper tertile (p  0.77). Similarly, a compa-
able proportion of patients died in each vessel size tertile
2.8% in the lower, 2.6% in the middle, and 2.8% in the
pper tertile; p  0.97).
The incidence of the primary end point of the study,
LR, was significantly different between the 3 study groups:
2 (12.1%) patients in the lower tertile compared with 58
8.4%) patients in the middle tertile and 52 (8.0%) patients
n the upper tertile required repeat revascularization proce-
ures (p  0.02). Most of the revascularization procedures
onsisted of repeat percutaneous interventions (11.5%
mong patients in the lower tertile, 7.7% in the middle
ertile, and 7.6% in the upper tertile; p  0.01). In the
ultivariate analysis that included all variables shown in
ables 1 and 2, vessel size tertile remained an independent
able 3. Results of Quantitative Angiographic Analysis at Follow
Characteristic
Lower Tertile
<2.41 mm
(n  548)
ate lumen loss
In-segment, mm 0.21  0.58
In-stent, mm 0.38  0.57
inimal lumen diameter
In-segment, mm 1.53  0.54
In-stent, mm 1.80  0.60
iameter stenosis
In-segment, % 35.18  20.93
In-stent, % 23.68  23.67
ngiographic restenosis
In-segment, no. (%) 107 (19.5)
In-stent, no. (%) 75 (13.7)
lus-minus values are mean  SD.igure 1. Late lumen loss in each vessel size tertile with sirolimus-eluting
tents and paclitaxel-eluting stents.
c
predictor of clinical restenosis (p  0.009). The model
howed a significant interaction between vessel size and type
f DES (p  0.008). More specifically, there was a
ignificant difference between the 2 DESs among patients
rouped in the lower tertile regarding TLR (8.6% with SES
s. 16.4% with PES; p  0.002), but not among those
rouped in the middle and upper tertiles (Fig. 2). Notably,
here were no significant differences between patients who
eceived SESs and those who received PES with respect to
nown risk factors for restenosis such as diabetes and lesion
ength that could explain the different incidence of TLR in
he lower tertile. The proportion of diabetic patients in the
ower tertile was 35.4% among SES patients and 33.1%
mong PES patients (p  0.54). Lesion length was 14.0 
.6 mm among SES patients and 13.5  7.8 mm among
ES patients (p  0.20). In addition, the proportion of
atients of the lower tertile treated with SES was compa-
able between the 2 participating centers: 52.3% in the First
edizinische Klinik rechts der Isar and 55.8% in the
eutsches Herzzentrum (p  0.43).
iddle Tertile
1 to 2.84 mm
(n  562)
Upper Tertile
>2.84 mm
(n  556) p Value
.20  0.57 0.24  0.62 0.29
.32  0.58 0.34  0.57 0.29
.91  0.54 2.38  0.61 0.001
.20  0.59 2.66  0.64 0.001
.26  18.21 28.27  16.43 0.001
.60  19.94 19.76  17.30 0.002
75 (13.3) 55 (9.9) 0.001
52 (9.3) 41 (7.4) 0.002
igure 2. Target lesion revascularization rate in each vessel size tertile with
irolimus-eluting stents and paclitaxel-eluting stents. Note that a signifi--Up
M
2.4
0
0
1
2
31
20ant difference between the 2 drug-eluting stents is only seen among
atients in the lower tertile.
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he results of the present study show that in patients
ndergoing SES or PES implantation vessel size does not
nfluence the risk of death or myocardial infarction but it is
n important determinant of the risk of restenosis. This
mpact of vessel size on the development of future clinical
estenosis is closely related to the type of DES implanted,
nd patients treated with SES for lesions located in small
essels have a smaller risk of requiring repeat revasculariza-
ion procedures compared with those treated with PES.
Patients with smaller vessels had several characteristics
e.g., a higher frequency of diabetes mellitus, multivessel
isease, chronic occlusions) that have been often associated
ith a poorer outcome after stent implantation. Neverthe-
ess, the findings from our large study population showed
hat patients with small vessels had a similar incidence of
eath and myocardial infarction compared with larger ves-
els, thus showing the safety of SES and PES implantation
rrespective of vessel size. On the other hand, patients
reated for lesions located in smaller vessels had a higher
requency of clinical and angiographic restenosis only when
reated with PES. Multivariate analysis confirmed the
ndependent influence of vessel size and its significant
nteraction with DES type regarding the risk of repeat
evascularization procedures during the 9-month clinical
ollow-up.
Previous studies with BMS have shown a similar degree
f late lumen loss across the whole range of vessel size (4).
rug-eluting stents have been shown to be an effective
reatment strategy for attenuating intimal hyperplasia, the
hief cause of restenosis and a major limitation of the
ong-term success of BMS (24,26). Indeed, in the early
eports on the use of DES, which included small numbers of
ery carefully selected patients, there was an almost com-
lete inhibition of neointimal hyperplasia, and therefore late
oss was almost absent (23,27–29). Based on these results,
nvestigators concluded that vessel size plays no role on the
evelopment restenosis after DES implantation (23).
eanwhile, other studies that included larger number of
atients with less restrictive criteria treated with DES
howed that late lumen loss occurs, albeit not to the same
egree with various DES, and that restenosis rates were
ower in vessels with bigger reference diameters (24,30).
owever, none of the aforementioned studies have specif-
cally addressed the role of vessel size on clinical and
ngiographic outcome. Moreover, previous analyses have
een based on patient populations that have received only a
articular DES, either SES or PES, and small to moderate
umbers of patients have been included. Instead, our
nalysis specifically focused on the impact of vessel size on
he outcome of 2,058 patients treated with both U.S. Food
nd Drug Administration–approved DES, with follow-up
ngiography being performed in 1,666 of these patients.
The results of this study provide solid evidence that
espite improved outcomes with DES compared with Gistorical data of BMS in small vessels, the size of the
eference diameter of the treated vessel has a major impact
n the risk of restenosis even in the era of DES. Although
linical and angiographic restenosis rates were similar
mong patients with vessel diameters 2.41 to 2.84 mm and
2.84 mm, restenosis rates were markedly higher among
atients with very small vessels (2.41 mm). Considering
he similar degree of in-stent late luminal loss regardless of
he reference diameter of the target vessel (ranging from
.32 to 0.36 mm), the reason for the difference in restenosis
ates between patients in the upper and middle vessel size
ertiles compared with those in the lower tertile is easily
nderstandable. Thus, the same extent of late loss that was
asily accommodated in larger vessels was great enough to
ead to an increased incidence of restenosis and need of
epeat revascularization procedures in smaller vessels.
Another important finding was the significant interaction
etween the 2 strongest predictors of clinical restenosis,
amely vessel size and type of DES used. Although clinical
estenosis rates were not significantly different between the
DES in patients grouped in the middle and upper tertiles,
eed of TLR was markedly lower with SES than PES in
atients with vessel size 2.41 mm. Indeed, late lumen loss
as significantly smaller with SES than with PES. Intu-
tively, in vessels with a similar size, a smaller late lumen loss
s more easily accommodated compared with a larger late
umen loss. These findings highlight the importance of
chieving maximal suppression of neointimal proliferation,
nd therefore, maximal reduction of late luminal loss with
ost effective DES (31,32) and echo the results of a recent
andomized study that showed that the better efficacy of
ES compared with PES was limited to the subset of very
mall vessels (33). On the other hand, these findings show
hat the use of PES was as effective as SES in about
wo-thirds of the present study population.
The present results add to the existing body of evidence
n the impact of vessel size on outcomes after percutaneous
oronary interventions. They show that for the treatment of
essels with a moderate to large reference diameter, the
election of a particular DES is not relevant. Recent
omparative studies have also shown that differences be-
ween BMS and DES are markedly reduced in larger vessels
7,34).
onclusions. The influence of vessel size on restenosis is
elated to the specific DES used. Small vessel size has a
egative impact on the outcome of patients treated with
ES. For lesions located in larger vessels, both SES and
ES provide comparably favorable results.
eprint requests and correspondence: Dr. Adnan Kastrati,
eutsches Herzzentrum, Lazarettstr. 36, 80636 Munich,
ermany. E-mail: kastrati@dhm.mhn.de.
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